A Study of ABT-751 in Patients With Colorectal Cancer
Completed · Phase 2
Conditions studied: Colorectal Cancer
In brief
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Key facts
- Study ID
- NCT00073138
- Run by
- Abbott
- People needed
- 40
- Starts
- 2003-08-01
- Expected to finish
- 2005-02-01
- Last updated by the study team
- 2007-11-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Colorectal cancer.
- Recurrent tumor following treatment with irinotecan and/or oxaliplatin.
- Able to tolerate normal activities of daily living.
- Adequate bone marrow, kidney, and liver function.
You may not qualify if…
- Pregnant or breast feeding.
- Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
- Prior radiation therapy.
- CNS metastasis.
Where it is running
- University of Southern California — Los Angeles, California, United States
- Cancer Institute Medical Group — Santa Monica, California, United States
- Northwestern University — Chicago, Illinois, United States
- University of Chicago Medical Center — Chicago, Illinois, United States
- Duke University Medical Center — Durham, North Carolina, United States
- University of Wisconsin Medical Center — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.